Huntingdon Life Sciences And Harlan Laboratories, Inc. Announce The Launch Of The SHrN™ Novel Hairless NOD.SCID Model At AACR 2015
Huntingdon (UK), 20 April 2015: Huntingdon Life Sciences and Harlan Laboratories today announced the launch of the SHrN™ – the world’s first hairless NOD.SCID mouse model to reach the market. SHrN™ is triple-immunodeficient and is ideally suited for humanization and tumor xenografts. The model, which has applications in oncology and immunology-related research, was developed for use by academic, government, biopharmaceutical, and contract research scientists. SHrN™ production will be managed in multiple Harlan facilities in the United States and Europe.
The SHrN™ combines several highly desirable characteristics into one research model. It has both a functional deficit in NK cells and a deficiency in T and B cells. Preliminary phenotyping results for SHrN™ have demonstrated promising benefits in cell uptake and tumor growth. Additionally, SHrNTM has the advantage of a marked decrease in cell leakage compared to other SCID models. Genetic consistency is ensured through inbreeding which limits unwanted variability in research efforts. Lastly, as a hairless model, the SHrNTM eliminates the need for shaving and enhances the observation of tumor growth and imaging clarity.
Dr. Adrian Hardy, Chief Operating Officer of the Huntingdon and Harlan organization, commented: “We are delighted to make available our innovative SHrNTM hairless NOD.SCID mouse to the worldwide research community. The new model will help our customers in their important research that leads to bringing innovative therapies to patients.”
“The SHrN™ was developed with the intent of improving both the effectiveness and convenience of the standard NOD.SCID model”, added Joe Meyer, Senior Vice President and General Manager of Harlan Laboratories, America’s: “At Huntingdon Life Sciences and Harlan Laboratories, we work closely with our customers to bring solutions to them that address gaps in the tools they use to support their research programs. As a consequence, we developed a NOD.SCID model that is hairless and slightly more immunocompromised to support the needs of scientists working in immunology, oncology, and other research areas.”
The company will introduce the SHrN™ at the AACR (American Association for Cancer Research) Annual Meeting in Philadelphia from April 19-22 – Harlan booth (#719). Researchers can access information about the new the new research model at www.harlan.com/shrn.
-ENDS-
Notes to editors
About Huntingdon Life Sciences
Huntingdon Life Sciences is a global provider of non-clinical contract research services to the pharmaceutical, crop protection and chemical industries. Huntingdon Life Sciences is a privately held company. www.huntingdon.com
About Harlan Laboratories
Harlan Laboratories, Inc. is a leading global provider of non-clinical contract research, research models, animal diets, and services to the pharmaceutical, biotech, medical device, crop protection and chemical industries, as well as universities, government, and other research organizations. Harlan Laboratories is a privately held company. www.harlan.com
For media enquiries, please contact:
Alex Heeley or Tristan Jervis
De Facto Communications
T: +44 207 203 6745 / 6740
E: a.heeley@defacto.com / t.jervis@defacto.com
Company contacts:
Katie Bramwell at Huntingdon Life Sciences
Phone: +44 (0) 1480 892748 Email: BramwellK@ukorg.Huntingdon.com
Andrew Gay at Huntingdon Life Sciences
Phone: + 44 (0) 1480 893073 Email: Sales@ukorg.Huntingdon.com
Help employers find you! Check out all the jobs and post your resume.
The SHrN™ combines several highly desirable characteristics into one research model. It has both a functional deficit in NK cells and a deficiency in T and B cells. Preliminary phenotyping results for SHrN™ have demonstrated promising benefits in cell uptake and tumor growth. Additionally, SHrNTM has the advantage of a marked decrease in cell leakage compared to other SCID models. Genetic consistency is ensured through inbreeding which limits unwanted variability in research efforts. Lastly, as a hairless model, the SHrNTM eliminates the need for shaving and enhances the observation of tumor growth and imaging clarity.
Dr. Adrian Hardy, Chief Operating Officer of the Huntingdon and Harlan organization, commented: “We are delighted to make available our innovative SHrNTM hairless NOD.SCID mouse to the worldwide research community. The new model will help our customers in their important research that leads to bringing innovative therapies to patients.”
“The SHrN™ was developed with the intent of improving both the effectiveness and convenience of the standard NOD.SCID model”, added Joe Meyer, Senior Vice President and General Manager of Harlan Laboratories, America’s: “At Huntingdon Life Sciences and Harlan Laboratories, we work closely with our customers to bring solutions to them that address gaps in the tools they use to support their research programs. As a consequence, we developed a NOD.SCID model that is hairless and slightly more immunocompromised to support the needs of scientists working in immunology, oncology, and other research areas.”
The company will introduce the SHrN™ at the AACR (American Association for Cancer Research) Annual Meeting in Philadelphia from April 19-22 – Harlan booth (#719). Researchers can access information about the new the new research model at www.harlan.com/shrn.
-ENDS-
Notes to editors
About Huntingdon Life Sciences
Huntingdon Life Sciences is a global provider of non-clinical contract research services to the pharmaceutical, crop protection and chemical industries. Huntingdon Life Sciences is a privately held company. www.huntingdon.com
About Harlan Laboratories
Harlan Laboratories, Inc. is a leading global provider of non-clinical contract research, research models, animal diets, and services to the pharmaceutical, biotech, medical device, crop protection and chemical industries, as well as universities, government, and other research organizations. Harlan Laboratories is a privately held company. www.harlan.com
For media enquiries, please contact:
Alex Heeley or Tristan Jervis
De Facto Communications
T: +44 207 203 6745 / 6740
E: a.heeley@defacto.com / t.jervis@defacto.com
Company contacts:
Katie Bramwell at Huntingdon Life Sciences
Phone: +44 (0) 1480 892748 Email: BramwellK@ukorg.Huntingdon.com
Andrew Gay at Huntingdon Life Sciences
Phone: + 44 (0) 1480 893073 Email: Sales@ukorg.Huntingdon.com
Help employers find you! Check out all the jobs and post your resume.